First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants

This study found BMS-986141 was safe and well tolerated, with dose-proportional pharmacokinetics and concentration-dependent pharmacodynamics in healthy participants over a wide dose range. ClinicalTrials.gov ID: NCT02341638.PMID:37394920 | DOI:10.1080/09537104.2023.2222846

Source: Platelets - July 3, 2023 Category: Hematology Authors: Samira Merali Zhaoqing Wang Charles Frost Stephanie Meadows-Shropshire Dara Hawthorne Jing Yang Dietmar Seiffert Source Type: research